Phase 1 × Stomach Neoplasms × Gynecologic × Clear all
NCT06910657 2026-03-02

IDOV-Immune for Advanced Solid Tumors

ViroMissile, Inc.

Phase 1 Recruiting
78 enrolled
NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
NCT05581004 2026-02-17

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

Phase 1 Recruiting
450 enrolled
NCT06242470 2026-02-05

A Study of MGC026 in Participants With Advanced Solid Tumors

MacroGenics

Phase 1 Recruiting
250 enrolled
NCT06781983 2026-01-07

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

Innate Pharma

Phase 1 Recruiting
145 enrolled
NCT05238883 2025-11-21

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

HiFiBiO Therapeutics

Phase 1 Active not recruiting
72 enrolled
NCT06336148 2025-10-15

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Actym Therapeutics, Inc.

Phase 1 Terminated
10 enrolled
NCT05107674 2025-09-09

A Study of NX-1607 in Adults With Advanced Malignancies

Nurix Therapeutics, Inc.

Phase 1 Recruiting
345 enrolled
NCT04458259 2025-08-28

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Pfizer

Phase 1 Terminated
88 enrolled
NCT03170960 2025-08-17

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Exelixis

Phase 1 Active not recruiting
914 enrolled
NCT07118176 2025-08-12

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Jonsson Comprehensive Cancer Center

Phase 1 Recruiting
30 enrolled
NCT04234113 2025-01-08

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Sotio Biotech Inc.

Phase 1 Terminated
115 enrolled
NCT04660929 2024-12-18

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Carisma Therapeutics Inc

Phase 1 Active not recruiting
48 enrolled